Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-NaE¯ve Patients with First-Line CLL/SLL.
In: PR Newswire, 2023-10-15
Zeitungsartikel
Zugriff:
Titel: |
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-NaE¯ve Patients with First-Line CLL/SLL.
|
---|---|
Zeitschrift: | PR Newswire, 2023-10-15 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|